NCT02320825 is a Phase 3 clinical trial of single-fraction SRS in Spinal Metastases, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT02320825?

NCT02320825 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT02320825?

Interventions in NCT02320825: single-fraction SRS, high-dose hypofractionated SRS, Quality of Life Measures.

What condition does NCT02320825 study?

NCT02320825 studies Spinal Metastases.

Is NCT02320825 still recruiting?

NCT02320825 is currently completed. Last updated 19 February 2019.

Are results published for NCT02320825?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-02-19 · How we verify

NCT02320825

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases

Completed Phase 3 Results posted Last updated 19 February 2019

What this trial tests

Phase 3 trial testing single-fraction SRS in Spinal Metastases in 16 participants. Completed in 26 July 2018.

Timeline

16 December 2014

Primary endpoint
26 July 2018

26 July 2018

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	16 December 2014
Primary completion	26 July 2018
Estimated completion	26 July 2018
Sites	4 locations across United States

Drugs / interventions tested

single-fraction SRS
high-dose hypofractionated SRS
Quality of Life Measures

Conditions studied

Spinal Metastases — all drugs for Spinal Metastases →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Spinal Metastases. Patients with the condition only — healthy volunteers not accepted.

Adverse events — posted to ClinicalTrials.gov

Time frame: 2 years. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

High-dose Hypofractionated SRS (27 Gy in 3 Fractions)

Serious: 1/8 (13%)

Deaths: 7/8

Single-fraction SRS (24 Gy)

Serious: 0/8 (0%)

Deaths: 5/8

Serious adverse events (1 terms)

Reaction	System	High-dose Hypofractionated…	Single-fraction SRS (24 Gy)
Esophagitis	Gastrointestinal disorders	—	—

Most-reported serious reactions: Esophagitis.

Data from ClinicalTrials.gov NCT02320825 adverse events section.

Sponsor's own description

The purpose of this study is to find out whether giving one higher dose of radiation is as good at treating the tumor in the patient's spine after surgery as giving three lower doses of radiation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Stereotactic spine radiosurgery: Review of safety and efficacy with respect to dose and fractionation.
Huo M, Sahgal A, Pryor D, Redmond K, et al · · 2017 · cited 37× · PMID 28303210 · DOI 10.4103/2152-7806.200581
Racial, ethnic, and socioeconomic disparities in clinical trial reporting for metastatic spine tumors: An exploration of North American studies.
Bangash AH, Fluss R, Eleswarapu AS, Fourman MS, et al · · 2025 · PMID 39969615 · DOI 10.1007/s10143-025-03343-1

Verify or expand the search:

Other recruiting trials for Spinal Metastases

Currently open trials in the same condition.

NCT06548061 — D20054;LITT for Spine Tumors · NA · recruiting
NCT06244264 — The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis · NA · recruiting
NCT06120426 — En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor · recruiting
NCT05575323 — Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases · NA · recruiting
NCT07429422 — SBRT Technique Implementation for Spinal Metastases Irradiation · NA · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02320825 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 19 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02320825.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing